Stefano Del Prato

Full Professor of Endocrinology

Università degli Studi di Roma Tor Vergata Facoltà di Medicina e Chirurgia

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (10)

Aris Liakos

Assistant Professor in Internal Medicine

Aristotle University of Thessaloniki

GREECE

View details

Seung Jae Baek

Chief Medical Officer

SOUTH KOREA

View details

Angelo Avogaro

ITALY

View details

Hertzel C. Gerstein

CANADA

View details

Angus Forbes

UNITED KINGDOM

View details

Kelley Branch

Professor

University of Washington

UNITED STATES

View details

Carolyn SP Lam

NETHERLANDS

View details

Domenico Tricò

ITALY

View details

FRANCESC XAVIER COS CLARAMUNT

Associate Professor

University of Barcelona

SPAIN

View details

Anna Solini

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stefano Del Prato

Research Interests

Explore related searches

Contact this professor

Articles (10)

Incretins and cardiovascular disease: to the heart of type 2 diabetes?

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials

Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial

The European Diabetes Forum (EUDF): a forum for turning the tide on diabetes in Europe

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening

Collaborators (10)

Aris Liakos

Seung Jae Baek

Angelo Avogaro

Hertzel C. Gerstein

Angus Forbes

Kelley Branch

Carolyn SP Lam

Domenico Tricò

FRANCESC XAVIER COS CLARAMUNT

Anna Solini

Make your next move.